Adaptive Biotechnologies Corp
NASDAQ:ADPT
Balance Sheet
Balance Sheet Decomposition
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp
Balance Sheet
Adaptive Biotechnologies Corp
| Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
85
|
55
|
97
|
123
|
139
|
90
|
65
|
48
|
70
|
|
| Cash Equivalents |
85
|
55
|
97
|
123
|
139
|
90
|
65
|
48
|
70
|
|
| Short-Term Investments |
107
|
110
|
480
|
565
|
214
|
408
|
281
|
174
|
156
|
|
| Total Receivables |
6
|
5
|
13
|
10
|
17
|
40
|
39
|
43
|
50
|
|
| Accounts Receivables |
6
|
5
|
13
|
10
|
17
|
40
|
38
|
42
|
50
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Inventory |
5
|
8
|
9
|
14
|
19
|
15
|
14
|
8
|
10
|
|
| Other Current Assets |
3
|
3
|
14
|
15
|
13
|
9
|
10
|
10
|
13
|
|
| Total Current Assets |
205
|
181
|
613
|
727
|
403
|
562
|
410
|
284
|
300
|
|
| PP&E Net |
14
|
19
|
60
|
139
|
173
|
164
|
120
|
94
|
75
|
|
| PP&E Gross |
14
|
19
|
60
|
139
|
173
|
164
|
120
|
94
|
0
|
|
| Accumulated Depreciation |
9
|
13
|
18
|
24
|
36
|
54
|
73
|
88
|
0
|
|
| Intangible Assets |
15
|
14
|
12
|
10
|
9
|
7
|
5
|
3
|
2
|
|
| Goodwill |
119
|
119
|
119
|
119
|
119
|
119
|
119
|
119
|
119
|
|
| Long-Term Investments |
9
|
0
|
105
|
119
|
217
|
0
|
0
|
34
|
13
|
|
| Other Long-Term Assets |
0
|
0
|
3
|
3
|
3
|
5
|
7
|
5
|
4
|
|
| Other Assets |
119
|
119
|
119
|
119
|
119
|
119
|
119
|
119
|
119
|
|
| Total Assets |
363
N/A
|
333
-8%
|
912
+174%
|
1 116
+22%
|
923
-17%
|
857
-7%
|
661
-23%
|
539
-18%
|
513
-5%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
2
|
2
|
5
|
3
|
3
|
8
|
8
|
7
|
6
|
|
| Accrued Liabilities |
4
|
7
|
10
|
27
|
30
|
37
|
32
|
34
|
34
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
5
|
|
| Other Current Liabilities |
15
|
14
|
63
|
75
|
81
|
64
|
49
|
56
|
45
|
|
| Total Current Liabilities |
21
|
23
|
78
|
105
|
114
|
110
|
88
|
98
|
90
|
|
| Long-Term Debt |
0
|
0
|
37
|
0
|
0
|
0
|
131
|
132
|
127
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
|
| Other Liabilities |
4
|
7
|
226
|
268
|
205
|
283
|
134
|
106
|
71
|
|
| Total Liabilities |
26
N/A
|
30
+16%
|
341
+1 041%
|
373
+9%
|
319
-14%
|
393
+23%
|
353
-10%
|
337
-5%
|
294
-13%
|
|
| Equity | ||||||||||
| Common Stock |
561
|
561
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
249
|
296
|
366
|
512
|
719
|
919
|
1 144
|
1 304
|
1 363
|
|
| Additional Paid In Capital |
25
|
38
|
936
|
1 254
|
1 324
|
1 387
|
1 453
|
1 506
|
1 582
|
|
| Other Equity |
0
|
0
|
1
|
1
|
1
|
4
|
0
|
0
|
0
|
|
| Total Equity |
337
N/A
|
303
-10%
|
571
+89%
|
743
+30%
|
604
-19%
|
464
-23%
|
308
-34%
|
203
-34%
|
219
+8%
|
|
| Total Liabilities & Equity |
363
N/A
|
333
-8%
|
912
+174%
|
1 116
+22%
|
923
-17%
|
857
-7%
|
661
-23%
|
539
-18%
|
513
-5%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
119
|
119
|
125
|
138
|
141
|
143
|
145
|
148
|
154
|
|